Anteris Technologies Ltd (ASX: AVR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Anteris Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $359.27 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 19.22 million
Earnings per share -4.310
Dividend per share N/A
Year To Date Return -2.87%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Anteris Technologies Ltd (ASX: AVR)
    Latest News

    Five healthcare workers standing together and smiling.
    Healthcare Shares

    2 ASX healthcare shares bucking the trend to hit new highs on Friday

    These healthcare shares are on form on Friday

    Read more »

    a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
    Healthcare Shares

    Anteris (ASX:AVR) share price soars 22% on successful human trial

    The company's shares are off to a strong start this week.

    Read more »

    woman looking at iPhone whilst working on a laptop
    Share Fallers

    Why the Anteris (ASX:AVR) share price backtracked 6% today

    Anteris shares slide after news of an impending share dilution.

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    Why is the Anteris (ASX:AVR) share price surging today?

    The Anteris Technologies Ltd (ASX: AVR) share price is rising today after the company announced its ComASUR Key Milestone report.

    Read more »

    falling healthcare asx share price Mesoblast capital raising
    Share Market News

    Anteris (ASX:AVR) share price drops 7% despite positive announcement

    The Anteris (ASX: AVR) share price has plunged 7.6% today despite a positive announcement from the medical company.

    Read more »

    Share Market News

    The Anteris (ASX:AVR) share price is down today but has soared 150% in 3 months

    The Anteris (ASX:AVR) share price exploded 150% higher over the past 3 months. Here's a summary of the latest results…

    Read more »

    investor looking excited at rising fortescue share price on laptop
    Share Market News

    Why the Anteris Technologies (ASX:AVR) share price soared 23% today

    The Anteris Technologies Ltd (ASX: AVR) share price rose an incredible 23% today after an online investor presentation yesterday.

    Read more »

    A boy with question mark on his forehead looking up as if watching an ASX share price
    Share Market News

    Why the Anteris (ASX:AVR) share price will be on watch today

    The Anteris Technologies (ASX:AVR) share price will be on watch this morning following the release of the company's latest results.

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    These 2 ASX healthcare shares popped today

    The All Ords is having a flat day but these 2 ASX healthcare shares have still managed to post some…

    Read more »

    soaring hydrix share price represented by doctor riding on top of heart high up in the clouds
    Share Market News

    Why the Anteris (ASX:AVR) share price is edging higher today

    The Anteris Technologies Ltd (ASX: ANV) share price is edging higher today after releasing the results from its anti-clarification study.

    Read more »

    a woman
    Record Highs

    Twiggy Forrest backed Invex Therapeutics has now doubled since its IPO

    Have you got as much cash to burn as Andrew Forrest?

    Read more »

    a woman
    Share Fallers

    Why the Admedus share price is sinking again on more big losses

    Admedus Ltd (ASX:AHZ) has been a sorry tale for shareholders.

    Read more »

    AVR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Anteris Technologies Ltd

    Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. It is also engaged in researchand development of ComASUR, a delivery system that allows accurate valve placement, and the manufacturing and selling of proprietary ADAPT regenerative tissue products. The company generates a majority of its revenue from the United Statesand the rest from Switzerland and Australia.

    AVR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 Jun 2024 $18.69 $0.09 0.48% 7,041 $18.62 $18.70 $18.45
    21 Jun 2024 $18.60 $-0.10 -0.53% 35,880 $18.70 $18.77 $18.21
    20 Jun 2024 $18.70 $-0.30 -1.58% 9,596 $19.00 $19.00 $18.62
    19 Jun 2024 $19.00 $0.11 0.58% 5,216 $19.01 $19.11 $18.59
    18 Jun 2024 $18.89 $0.14 0.75% 14,880 $18.75 $19.16 $18.70
    17 Jun 2024 $18.75 $-1.20 -6.02% 7,561 $20.00 $20.00 $18.75
    14 Jun 2024 $19.95 $0.20 1.01% 9,187 $19.95 $20.00 $19.83
    13 Jun 2024 $19.75 $0.45 2.33% 16,019 $19.50 $19.99 $19.50
    12 Jun 2024 $19.30 $0.25 1.31% 6,761 $19.05 $19.50 $18.90
    11 Jun 2024 $19.05 $0.05 0.26% 11,952 $19.15 $19.15 $18.60
    07 Jun 2024 $19.00 $0.10 0.53% 4,377 $18.88 $19.00 $18.59
    06 Jun 2024 $18.90 $-0.20 -1.05% 8,851 $18.98 $19.20 $18.70
    05 Jun 2024 $19.10 $0.09 0.47% 6,904 $18.82 $19.13 $18.80
    04 Jun 2024 $19.01 $-0.04 -0.21% 2,091 $19.00 $19.01 $18.77
    03 Jun 2024 $19.05 $0.05 0.26% 4,185 $18.91 $19.09 $18.77
    31 May 2024 $19.00 $0.25 1.33% 30,419 $18.51 $19.09 $18.25
    30 May 2024 $18.75 $-0.23 -1.21% 9,566 $19.00 $19.00 $18.52
    29 May 2024 $18.98 $-0.22 -1.15% 10,801 $19.10 $19.45 $18.80
    28 May 2024 $19.20 $0.35 1.86% 9,632 $19.00 $19.20 $18.52
    27 May 2024 $18.85 $-0.15 -0.79% 5,610 $19.00 $19.20 $18.72

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    22 Mar 2024 Stephen (Steve) Denaro Cancelled 8,500 $194,990
    Cancellation of securities.
    22 Mar 2024 John Seaberg Cancelled 20,000 $458,800
    Cancellation of securities.
    22 Mar 2024 Wayne Paterson Cancelled 117,000 $2,683,980
    Cancellation of securities.
    15 Sep 2023 Wenyi Gu Issued 80,500 $1,634,150
    Issue of options.
    15 Sep 2023 Stephen (Steve) Denaro Issued 80,500 $1,634,150
    Issue of options.
    15 Sep 2023 Wayne Paterson Issued 700,000 $14,210,000
    Issue of options.
    15 Sep 2023 John Seaberg Issued 157,500 $3,197,250
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Stephen (Steve) Denaro Company SecretaryNon-Executive Director Oct 2018
    Mr. Denaro has been providing company secretarial services to other ASX-listed companies since 1994 and serves as a director and sole shareholder of Trio Business Intermediaries Pty Ltd, a business consulting company, specialising in restructuring, corporate governance, directorship and company secretarial services, through which he provides these and other services. Mr. Denaro has over 25 years of experience in mergers and acquisitions, business valuations, accountancy services, and income tax compliance gained from positions as Company Secretary and Chief Financial Officer of public companies and with chartered accountancy firms in Australia and the United Kingdom. He is chair of risk management committee.
    Mr John Seaberg Non-Executive DirectorNon-Executive Chairman Oct 2014
    Mr. Seaberg has been serving as Board Chair of Preceptis Medical Inc since 2016 and Phraxis Medical Inc since 2009. He was Executive VP at Cedar Point Capital, a broker-dealer focused on healthcare investment from June 2015 through December 31, 2023. From 2008 until 2012, Mr. Seaberg was Chair of Synovis Inc., a NASDAQ-listed manufacturer of medical device and bio scaffold tissue products which was acquired by Baxter, and, from 2007 until 2014, was Co-Founder, Chair and Chief Executive Officer of NeoChord Inc., a company commercialising technology developed at the Mayo Clinic for repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr. Seaberg served at Guidant Corp. (subsequently acquired by Boston Scientific Corp.) where he held executive level positions, including Director of Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In addition, Mr. Seaberg was co-Founder, President and Chief Executive Officer of ACIST Medical, from 1991 to 1995. He is member of risk management committee.
    Mr Wayne Paterson Managing DirectorChief Executive Officer Feb 2016
    Mr. Paterson held senior positions at Merck KGaA (Merck), a science and technology company, from 2005 to 2013, including as President of Europe, Canada and Australia, President of Emerging Markets, President of Japan and President of Cardiovascular Medicine. From 1999 until 2005, Mr. Paterson served at Roche Pharmaceuticals, a multinational healthcare company, in several senior positions, including as Head of Pharmaceuticals in Roche's South Korean operation and Head of Commercial Operations for Roche China.
    Dr Wenyi Gu Non-Executive Director Oct 2018
    Dr. Gu is currently guest professor with several Chinese institutes and universities. Since January 2017, Dr. Gu has been working as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland. In addition, from April 2021 to March 2023, Dr. Gu was the Chief Scientific Officer of Guangzhou Gillion Biotherapeutics Ltd, a biotechnology company. From 2006 to 2009, he held a Perter Doherty Fellowship and was supported by the National Health and Medical Research Council to work at Harvard Medical School as a visiting research fellow. Dr Gu is member of risk management committee.
    Matthew McDonnell Chief Financial Officer
    -
    David St Denis Chief Operating Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited A/C 2 3,441,479 19.02%
    Perceptive Life Sciences Master Fund Ltd 1,840,000 10.17%
    Citicorp Nominees Pty Limited 1,476,367 8.16%
    HSBC Custody Nominees (Australia) Limited 546,699 3.02%
    Evolution Capital Advisors Pty Ltd 486,387 2.69%
    Hsbc Custody Nominees (Australia) Limited <Gsco Customers A/C> 407,505 2.25%
    Mr Ricky Steven Neumann 380,270 2.10%
    Mr Patrick Chew 343,355 1.90%
    BNP Paribas Nominees Pty Ltd <IB Au Noms Retailclient> 325,076 1.80%
    Mutual Trust Pty Ltd 271,411 1.50%
    Ltl Capital Pty Ltd 266,761 1.47%
    Bnp Paribas Noms Pty Ltd <Global Markets> 261,779 1.45%
    Mishtalem Pty Ltd 211,500 1.17%
    Ubs Nominees Pty Ltd 176,988 0.98%
    BNP Paribas Noms Pty Ltd 176,560 0.98%
    Amedan Pty Ltd 175,000 0.97%
    Merrill Lynch (Australia) Nominees Pty Limited 159,297 0.88%
    Mr David Lamm 125,000 0.69%
    Dr Gary Owen Rooke 115,000 0.64%
    Hsbc Custody Nominees (Australia) Limited Gsco Eca 113,540 0.63%

    Profile

    since

    Note